Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
Nanobiotix announced its total outstanding shares as of
- 34,825,872 total outstanding shares enhances transparency.
- Total voting rights show significant investor engagement with gross at 35,999,095.
- Lead product NBTXR3 has received market authorization in Europe, indicating regulatory approval and commercial potential.
- None.
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
Date |
Number of Shares
|
Total number of voting rights |
|
Total voting rights,
|
Total voting rights,
|
||
|
34,825,872 |
35,999,095 |
35,984,023 |
(1) The total number of gross (or “theoretical”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
(2) The total number of net (or “exercisable at a Shareholders’ Meeting”) voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of
***
About
The company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003,
The company's resources are primarily devoted to the development of its lead product candidate–NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in
For more information about
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006210/en/
VP, Communications
+1 (617) 852-4835
contact@nanobiotix.com
Nanobiotix Investor Relations
SVP, Investor Relations
+1 (609) 678-7388
investors@nanobiotix.com
Media Relations
+ 33 (0) 6 64 79 97 51
plgermain@ulysse-communication.com
US – Porter Novelli
+1 (781) 888-5106
dan.childs@porternovelli.com
Source:
FAQ
What is the number of outstanding shares for Nanobiotix as of February 28, 2022?
What are the total voting rights for Nanobiotix?
What is the ticker symbol for Nanobiotix on NASDAQ?